Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunologic therapy for secondary and primary progressive multiple sclerosis].

Kyoko Ozawa1

  • 1Department of Neurology, Utano National Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 10, 2003
PubMed
Summary

Immunotherapies like interferon-beta show benefits for secondary progressive multiple sclerosis (SPMS) by reducing relapses and lesions. However, effective treatments for primary progressive MS and axonal injury remain challenging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Japanese Case of Food Protein-induced Enterocolitis Syndrome Caused by Multiple Seafoods.

The Kobe journal of medical sciences·2024
Same author

Impacts of Perinatal Dioxin Exposure on Motor Coordination and Higher Cognitive Development in Vietnamese Preschool Children: A Five-Year Follow-Up.

PloS one·2016
Same author

Successful treatment of plasma exchange for severe cerebral venous thrombosis with thyrotoxicosis.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2009
Same author

Transient directional disorientation as a manifestation of cerebral ischemia.

European neurology·2008
Same author

Association between gastric atrophy and Helicobacter pylori infection in Japanese children: a retrospective multicenter study.

Digestive diseases and sciences·2006
Same author

A family of Emery-Dreifuss muscular dystrophy with extreme difference in severity.

Pediatric neurology·2005

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Context:

  • Progressive multiple sclerosis (MS) presents significant challenges in treatment, particularly for the primary progressive form.
  • Understanding the immunological underpinnings of MS is crucial for developing effective therapies.

Purpose:

  • To review current immunological treatments for progressive multiple sclerosis (MS).
  • To evaluate the efficacy of interferon-beta (IFN-β) and mitoxantrone in different MS subtypes.
  • To highlight the need for treatments addressing axonal injury in MS.

Summary:

  • Interferon-beta 1b (IFN β-1b) and interferon-beta 1a (IFN β-1a) trials in secondary progressive MS (SPMS) demonstrated benefits in reducing relapse rates and MRI lesions.
  • Mitoxantrone, an immunosuppressant, has also shown potential in slowing disability progression in SPMS.

Related Experiment Videos

  • Currently, no disease-modifying treatments are convincingly effective for primary progressive MS.
  • Axonal injury is a key pathological feature in MS, contributing to irreversible disability.

    • Impact:

    • Recent advancements offer hope for managing SPMS, but a significant unmet need exists for primary progressive MS.
    • Future therapeutic strategies must target both inflammation and demyelination, as well as axonal loss, to combat MS progression and disability.